ACUT (Accustem Sciences) Short-Term Debt: $0.00 Mil (As of Mar. 2026)


ACUT Accustem Sciences Inc ACUT
27 GF Score
Price $0.19
! 1 Warning Sign
View Full Analysis

What is Accustem Sciences Short-Term Debt?

Accustem Sciences ACUT +21.61% 27 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates ACUT with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Accustem Sciences's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Accustem Sciences's quarterly Short-Term Debt declined from Sep. 2025 ($0.05 Mil) to Dec. 2025 ($0.02 Mil) and declined from Dec. 2025 ($0.02 Mil) to Mar. 2026 ($0.00 Mil).

Accustem Sciences's annual Short-Term Debt declined from Dec. 2023 ($0.06 Mil) to Dec. 2024 ($0.03 Mil) and declined from Dec. 2024 ($0.03 Mil) to Dec. 2025 ($0.02 Mil).

Accustem Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Accustem Sciences Short-Term Debt Related Terms

Accustem Sciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Accustem Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accustem Sciences Short-Term Debt Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Short-Term Debt
0.11 0.06 0.03 0.02

Accustem Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.07 0.05 0.02 0.00
ACUT
27GF Score
Accustem Sciences Inc ACUT
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Accustem Sciences (ACUT) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Accustem Sciences' Short-Term Debt too high?
Accustem Sciences' current Short-Term Debt is $0.00 Mil. Overall, Accustem Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Accustem Sciences' Short-Term Debt compare to DCOY and BIXT?
Accustem Sciences' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Accustem Sciences's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accustem Sciences stock overvalued right now?
Accustem Sciences (ACUT) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Accustem Sciences' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Accustem Sciences (ACUT), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accustem Sciences Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10001
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
27GF Score

Get the complete analysis for ACUT

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price